Does Intensity Modulation Improve Healthy Tissue Sparing in Stereotactic Radiosurgery of Complex Arteriovenous Malformations?
Brenda Clark, Sara Erridge(The University of Texas MD Anderson Cancer Center), E. Vollans(BC Cancer Agency), Brian Toyota(University of British Columbia), James L. Robar(BC Cancer Agency), Andrew Lee(Flinders University), Roy Ma(BC Cancer Agency), C. Candish(BC Cancer Agency), Michael McKenzie(Provincial Health Services Authority), Karen Goddard(BC Cancer Agency)
Cited by 10
Related Papers
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2017|319